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ABSTRACT
The effect of 4-cii-hydroxy-L-proline (CHP), a proline analogue, on
the anchorage-dependentand -independentgrowth of several transformed
rodent cell lines was studied. Mouse NIH-3T3 fibroblasts transformed
by a variety of different oncogenes (Ki-ruv,max, src, fins, fes, met, and
trk) by a DNA tumor virus (SV 4(1) or by a chemical carcinogen (:V-
methylnitrosourea) were all found to be more sensitive (50% inhibitory
dose, 20 to 55 fig/ml) to the dose-dependent inhibitory effects of CHP on
growth in monolayer culture than were NIH-3T3 cells (50% inhibitory
dose, 120 pg/ml). CHP was generally found to be even more effective in
inhibiting the growth of these transformed cells as colonies in soft agar
than in monolayer cultures. In addition, rat embryo fibroblasts (CREF)
and normal rat kidney fibroblasts (NRK) after transformation with a Ki-
ras oncogene exhibit a similar increase in their sensitivity to ('III'-
induced growth inhibition. Treatment of NRK cells with transforming
growth factor a (TGF-a) and 0 (TGF-/8), which reversibly induces
phenotypic transformation of these cells, increases their sensitivity to
CHP to a level comparable with that observed in Ki-ros-transformed
NRK cells (K-NRK). The growth inhibitory effects of CHP are reversible,
since removal of CHP results in a normal resumption of cell growth.
CHP uptake occurs primarily through the Na*- and energy-dependent
neutralamino acid transport A system, which is 6- to 7-fold more elevated
in K-NRK cells compared with NRK cells. Treatment of NRK cells with
TGF-a and/or -ft increases the uptake of |3H]methylaminoisobutyricacid
on the A system to a level that is similar to that found in K-NRK cells.
The functions of the Na+/K* and Na*/I I* exchange systems are appar
ently necessary for the enhanced A system activity, since ouabain and
amiloride can inhibit the uptake of | 'II|mcihylaniinnisonutyricacid in K-
NRK cells and in NRK cells treated with TGF-a and/or -fi. The activity
of the A system is specifically increased in K-NRK and in TGF-a- and/
or -0-treated NRK cells, since the other two major neutral amino acid
uptake systems, the ASC and the L systems, and the l.y* system for
basic amino acid uptake show no apparent changes in their activity in
NRK cells after treatment with TGF-a and/or -fi or in these cells after
transformation with the Ki-ra.voncogene. These results suggest that the
differential growth sensitivity to CHP of transformed rodent cells and of
normal fibroblasts treated with TGF-a and/or -ti is due in part to an
elevated uptake of this amino acid analogue on the neutral amino acid
transport A system.
INTRODUCTION
CHP2 is a proline analogue that can be taken up by cells and
incorporated during protein synthesis in place of proline. This
event can interfere with the normal production and maturation
of proteins that are rich in proline, such as collagen (1). In fact,
CHP is known to be an inhibitor of collagen synthesis, because
the incorporation of this amino acid analogue into procollagen
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blocks the normal posttranslational hydroxylation of proline
residues that are essential for the stabilization of the triple
helical configuration of the mature native molecule. The result
ing nonhelical collagen that contains CHP in place of trans-
hydroxyproline is apparently retained within the cell and is
ultimately degraded (2). Collagen production and secretion are
essential for the growth and survival of several types of cells in
vivo and in vitro (3, 4). For example, CHP can inhibit the
growth of normal mammary epithelial cells and can cause
regression of well-differentiated rat mammary adenocarcino-
mas by inhibiting the production of collagen (5, 6). However,
it is not yet clear whether CHP can differentially affect the
growth of other normal and nontransformed cells or whether
the response of normal cells to CHP can be modulated by serum
growth factors.
Proline uptake occurs primarily through the neutral amino
acid transport A system. This Na+- and energy-dependent path
way is one of the most extensively regulated cell membrane
transport systems (7, 8). In normal cells, for example, the
activity of the A system can be modulated by a variety of agents,
including hormones and growth factors (9-11). In contrast,
most of these adaptive responses to environmental agents are
lost in transformed cells. After transformation, the A system
activity is constitutively elevated (12-16).
The present study was undertaken to determine whether CHP
can affect the growth of several rodent cell lines transformed
by various retroviral oncogenes, by a DNA tumor virus, or by
a chemical carcinogen. In addition, the study was designed to
assess whether normal cells, such as NRK cells, a normal rat
kidney cell line, can be sensitized to the effects of CHP by
treatment with TGF-a and -ÃŸ.These latter growth factors were
selected because NRK cells treated with TGF-a and -ÃŸare able
to grow as colonies in soft agar and assume a transformed
morphology in monolayer (17,18). These two phenotypic prop
erties are characteristic of transformed cells. TGF-a and -ÃŸare
two growth factors that have been circumstantially implicated
as proximal effectors of transformation for several different
oncogenes (19, 20).
The results of this study demonstrate that transformed cells
are more sensitive to the growth inhibitory effects of CHP than
are their normal nontransformed counterparts. This phenome
non may be due in part to an elevated uptake of CHP through
the neutral amino acid transport A system after transformation
or after treatment of normal cells with TGF-a and/or -ÃŸ.
MATERIALS AND METHODS
Chemicals. Culture media, antibiotics, trypsin, and FBS were ob
tained from GIBCO (Grand Island, NY). CHP was from Calbiochem-
Behring Corp. (La Jolla, CA). [3H]MeAIB (specific activity, 35 to 50
Ci/mmol), [3H]alanine(specific activity, 40 to 60 Ci/mmol), [3H]leucine
(specific activity, 45 to 70 Ci/mmol), and [3H]lysine (specific activity,
75 to 100 Ci/mmol) were obtained from Amersham (Arlington Heights,
IL). Nonlabeled amino acids were purchased from Sigma (St. Louis,
MO). Bovine insulin and human transferrin were obtained from Col
laborative Research (Lexington, MA); porcine TGF-/3 was from R and
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D Systems (Minneapolis, MM), and human recombinant TGF-Â«was
generously provided by Dr. Rik Derynck, Department of Molecular
Biology, Genentech (San Francisco, CA).
Cell Lines. Mouse NIH-3T3 clone 7 cells were provided by Dr. D.
Lowy, National Cancer Institute (Bethesda, MD). /nas-NIH-3T3 is a
clone of NIH-3T3 cells transformed with the Moloney murine sarcoma
virus; Ki-raj-NIH-3T3 are NIH-3T3 cells transformed with the Kirsten
murine sarcoma virus; Cl 1 and F2 are two clones of nontransformed
cellular revenants isolated from Kirsten murine sarcoma virus-trans
formed NIH-3T3 cells (21).//Â»Ã•-NIH-3T3 are NIH-3T3 cells trans
formed with McDonough strain of the feline sarcoma virus and were
provided by Dr. C. Sherr, National Cancer Institute. /es-NIH-3T3 are
NIH-3T3 cells transformed with the ST strain of the feline sarcoma
virus and were provided by Dr. J. Evan, National Cancer Institute, src-
NIH-3T3 are NIH-3T3 cells transfected and transformed with a plas-
mid carrying the v-src oncogene and were provided by Dr. S. Anderson,
State University of New York (Stony Brook, NY). m<?/-NIH-3T3 are
NIH-3T3 cells transfected and transformed with a plasmili containing
the human met oncogene and were provided by Dr. G. Vande Woude,
Frederick Cancer Research Facility, National Cancer Institute (Fred
erick, MD). rr*-NIH-3T3 are NIH-3T3 cells transfected and trans
formed with a plasmid containing the human trk oncogene and were
provided by Dr. M. Barbacid, Frederick Cancer Research Facility.
SV40-NIH-3T3 is a clone of NIH-3T3 cells infected and transformed
with the SV40 virus. NMU-NIH-3T3 are NIH-3T3 cells transformed
by treatment with the chemical carcinogen NMU. CREF is a normal
rat embryo fibroblast cell line that was kindly provided by Dr. P.
Fischer, Columbia University (New York, NY). K-CREF are CREF
cells transformed with the Kirsten murine sarcoma virus. NRK cells
are a normal rat kidney fÃ¬broblastcell line that was obtained from Dr.
J. DeLarco, National Cancer Institute. K-NRK cells are NRK cells that
have been transformed with the Kirsten murine sarcoma virus.
NMuMg, a normal mouse mammary epithelial cell line, and NMuMg-
Ha-ras, a transformed derivative of NMuMg, were obtained by trans-
fection of NMuMg cells with a plasmid containing the human activated
c-Ha-rai proto-oncogene and were provided by Dr. N. Hynes, Ludwig
Institute for Cancer Research (Bern, Switzerland) (22).
All cell lines were grown in DMEM supplemented with 10% FBS
containing 4 mM glutamine, 20 mM 4-(2-hydroxyethyl)-l-piperazine-
ethane sulfonic acid, pH 7.4, streptomycin (100 Â¿tg/ml),and penicillin
(100 units/ml) in a humidified atmosphere of 95% air and 5% CO2 at
37'C.
Monolayer Growth. Cells were plated in 12 multiwell cluster dishes(Costar, Cambridge, MA) at a density of 2 x IO4 to 5 x IO4 cells per
well in 2 ml of DMEM containing 10% FBS. Twenty-four h later, they
were treated with different concentrations of CHP. After 3 days of
treatment, the cells were trypsinized and counted in a Coulter counter
(model ZBI).
Soft Agar Growth. Cells (2 x 10" per dish) were seeded in 1 ml of
0.3 Difco Noble agar that was supplemented with DMEM and 10%
FBS. This suspension was layered over 1 ml of 0.8% agar medium base
layer in 35-mm dishes (Costar) and treated with different concentrations
of CHP. After 12 days, the cells were stained with nitro blue tetrazo-
lium, and colonies larger than 50 ^m were counted with an Artek model
880 colony counter (Artek Systems Corporation, Farmingdale, NY).
Effects of TGF-a and TGF-0 on NRK Cell Growth. The growth
response of NRK cells to CHP in the absence or in the presence of
TGF-a (2 ng/ml) and/or TGF-/3 (2 ng/ml) was evaluated in monolayer
cultures or in soft agar as described above. For serum-free anchorage-
dependent growth, cells were allowed to attach to the wells in DMEM
containing 10% FBS. Twenty-four h later, the cells were washed and
incubated with IMEM containing 4 mM glutamine, 20 mM 4-(2-hy-
droxyethyl)-l-piperazineethane sulfonic acid, pH 7.4, streptomycin
(100 Mg/ml), penicillin (100 units/ml), bovine insulin (10 ^g/ml), and
human transferrin (10 ijg/ml) in the absence or presence of TGF-Â«(2
ng/ml) and/or TGF-/3 (2 ng/ml) and exposed to different concentrations
of CHP. After 3 days of treatment, the cells were trypsinized and
counted in a Coulter counter.
Amino Acid Transport Measurement. The transport assays were
essentially performed as previously described by Boerner and Saier (15)
with the following modifications. Cells (4 x IO4)were seeded in 6-well
cluster dishes (Costar) in 3 ml of DMEM with 10% FBS. After 24 h,
the cells were washed with serum-free DMEM and cultured in serum-
free IMEM containing human transferrin (10 Mg/ml) for 16 h. The
cells were then treated for the indicated time periods with or without
TGF-Â«(2 ng/ml) and/or TGF-f) (2 ng/ml). Before measuring amino
acid uptake, the cells were washed and incubated at 37Â°Cfor 30 min in
transport buffer (10 mM Tris-HCI, pH 7.4, 1 mM MgCI2, 2 mM CaCl2,
5 mM KC1, 135 mM NaCI, and 5 mM glucose). Amino acid uptake was
initiated by incubating the monolayer cultures in transport buffer con
taining 3 to 5 /<( i of the radiolabeled amino acid at a concentration of
0.1 mM. After 3 min the uptake of pHjMeAIB was terminated and,
after 1 min, the uptake of ['Hjalanine, ['H]leucine, and ['Hjlysine.
Preliminary experiments have shown that uptake was linear during
these periods of time for each of the respective radiolabeled amino
acids (data not shown). The cells were then extracted with 1.5 ml of
ice-cold 10% trichloroacetic acid, and the trichloroacetic acid-soluble
amino acids were counted in 10 ml of Hydrofluor scintillation fluid
(National Diagnostics, Somerville, NJ) using a Beckman scintillation
counter. Total uptake was corrected for nonspecific uptake by measur
ing the amount of radiolabeled amino acid taken up in the presence of
a 250-fold excess of unlabeled amino acid. The data were normalized
on the basis of the cell numbers. For | 'I l|;ilanmr uptake on the ASC
system, the assays were performed at pH 6.0 with transport buffer
containing 0.1 mM MeAIB to inhibit alanine transport through the A
system (15). For ('H)leucine and ['H]lysine uptake, the assays were
performed at pH 7.4 with transport buffer containing 135 mM choline
chloride instead of NaCI to ensure the specific uptake through the L
and Ly+ systems, respectively (14, 15).
RESULTS
Effects of CHP on the Growth of Rodent Cell Lines. High
concentrations of CHP (greater than 400 yug/ml) have been
shown to inhibit amino acid incorporation during protein syn
thesis (1). However, low concentrations of this amino acid
analogue (less than 100 ^g/ml) were able to specifically inhibit
the synthesis and secretion of proline-rich proteins, such as
collagen (1, 2). Therefore, the effects of low doses of CHP (5-
150 Mg/ml) on the anchorage-dependent and -independent
growth of a variety of normal and transformed rodent cell lines
were assayed. As shown in Table 1, the anchorage-dependent
growth in monolayer cultures of mouse NIH-3T3 cells trans
formed by several different retroviral oncogenes (Ki-ras, src,
fes, fms, mos) by two activated cellular protooncogenes (met,
trk), a DNA tumor virus (SV40), and a chemical carcinogen
(NMU) is 2- to 6-fold more sensitive to the growth inhibitory
effects of CHP compared with normal NIH-3T3 cells. For
example, to achieve a 50% inhibition of growth of Ki-ras-NIH-
3T3 cells requires approximately 20 Â¿ig/mlof CHP, whereas
120 Mg/ml are necessary for eliciting the same degree of re
sponse in NIH-3T3 cells. Two nontransformed cellular reven
ants, Cil and F2, that were derived from viral Ki-rai-trans-
formed NIH-3T3 cells are relatively insensitive to the growth
inhibition induced by CHP (ID50, 120 and 125 Mg/ml, respec
tively) like the parental NIH-3T3 cells. These two revenants
are morphologically flat, exhibit contact inhibition of cell
growth, do not grow as colonies in soft agar, and are not
tumorigenic in vivo (21). As shown in Table 1, the majority of
the transformed cells are generally 2- to 5-fold more sensitive
to the growth inhibitory effects of CHP in soft agar than in
monolayer cultures.
A similar degree of differential growth inhibition induced by
CHP was also observed between two normal rat fibroblast cell
lines, CREF and NRK (IDâ„¢,100 and 90 /ug/ml, respectively),
and their counterparts that had been transformed by a viral Ki-
ras oncogene, K-CREF and K-NRK (ID50, 50 fig/ml). The
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Table I Effects of CHP on anchorage-dependent and -independent growth of
rodent cell lines
CelllineMouse
fibroblastsN1H-3T3Cl
1 (Ki-ras N1H-3T3 cellularrevenant)F2
(Ki-ros NIH-3T3 cellularrevenant)Â«T- I -3 3moj-NIH-3T3II-A-NIH-3T3/ms-NIH-3T3Â«Â«-NIH-3T3/Â«-NIH-3T3Ki-raj-NIH-3T3SV40-NIH-3T3NMU-NIH-3T3Mouse
epithelialcellsNMuMgNMuMg-Ha-rosRat
fibroblastsCREFK-CREFNRKK-NRKIDÂ»
(ng/Monolayer*120
(Â±5)120
(Â±4)125
(Â±6)100
(Â±2)50
(Â±3)50
(Â±2)40
(Â±4)30
(Â±3)20
(Â±1)20
(Â±4)25
(Â±2)20
(Â±1)25055
(Â±2)100
(Â±5)50
(Â±2)90
(Â±2)50
(Â±1)'ml)'AgarrNA*NANA30
(Â±5)5
(Â±2)55
(Â±5)25
(Â±2)40
(Â±1)5
(Â±2)10(Â±1)in
( ' 115(Â± )NA35
(Â±1)NA5
(Â±2)NA15
(Â±2)
" Dose that is able to produce a 50% reduction in growth compared with
untreated control cultures. Derived from dose-response experiments in which the
cells were treated with different concentrations (5 to 150 fig/ml) of CHP. Values,
average (Â±SD)of quadruplicate determinations.
* Cells (5 x IO4per well) were seeded in 12 multiwcll cluster dishes. After 24
h, they were treated with different concentrations of CHP and counted after 3
days of exposure.
c Cells (2 x 10*per well) Â»ereseeded in 35-mm dishes in 0.3% agar containing
DMEM and 10% FBS and treated with different concentrations of CHP. After
12 days, the colonies were stained with nitro blue tetrazolium and counted with
an Artek 880 colony counter.4 NA, not assayable because the cells do not grow as colonies in soft agar.
selective growth inhibition by CHP is not restricted to fibro
blasts, since a normal mouse mammary epithelial cell line,
NMuMg, is relatively insensitive to growth inhibition induced
by CHP (ID50, 250 /Â¿g/ml).However, these cells acquire an
approximately 5-fold enhanced sensitivity to CHP after trans
formation with an activated c-Ha-ras oncogene (ID50, 50 /Â¿g/
ml) (Table 1).
Effects of TGF-a and/or TGF-0 on CHP Sensitivity of NRK
Cells. Several different retroviral oncogenes or activated cellular
protooncogenes have been shown to induce the production of
growth factors such as the TGFs, which may be involved in
mediating the action of these oncogenes (18-20). NRK cells
are a nontransformed rat kidney fibroblast cell line that can be
phenotypically transformed by treatment with TGF-a and -ÃŸ
(17, 18). In the presence of TGF-a and -ÃŸ,these cells lose
contact inhibition of growth in monolayer cultures and are able
to grow as colonies in semisolid medium ( 17). For these reasons,
we chose NRK cells as a model system for studying the effects
of TGF-a and -ÃŸon modulating the intrinsic growth sensitivity
of nontransformed cells to CHP.
Fig. 1 illustrates the morphology of control NRK cells, TGF-
a-treated NRK cells (2 ng/ml), and K-NRK cells grown in the
absence or presence of CHP (50 Mg/ml) for 3 days in medium
containing 10% FBS. This concentration of TGF-a, 2 ng/ml,
was previously found to be optimal for stimulating the anchor
age-dependent growth and for promoting the anchorage-inde
pendent growth of NRK cells in soft agar (23). Compared with
normal NRK cells (Fig. 1/4), TGF-a-treated NRK cells (Fig.
1C), and ras-transformed NRK cells, K-NRK cells (Fig. \E)
have a similar morphology in that both populations of cells
exhibit a fusiform morphology and tend to pile up on each
other at confluency. After treatment with CHP, NRK cells
exhibit little or no change in their morphology (Fig. 1Ã„),
whereas TGF-a-treated NRK cells (Fig. ID) and K-NRK cells
(Fig. \F) exhibit a flat morphology. In this experiment, as well
as in others conducted in the presence of serum, we found that
TGF-a alone was sufficient to produce these morphological
changes in NRK cells, presumably because there are sufficient
amounts of TGF-/Ãœand other growth factors, such as platelet-
derived growth factor and insulin-like growth factor I, already
present in serum (24).
The growth inhibitory effects of CHP on cells are also dose
dependent both in monolayer culture and in semisolid medium
(Fig. 2). K-NRK cells are about 2.5-fold more sensitive to CHP
than NRK cells in monolayer cultures in medium containing
10% FBS (ID50, 35 and 90 Mg/ml, respectively) (Fig. 2A).
Treatment of NRK cells with TGF-Â« (2 ng/ml) for 3 days
increases the sensitivity of these cells to the growth inhibitory
effects of CHP to the same degree as that observed in K-NRK
cells, since it shifts the 1D50from 90 to 34 ng/ml (Fig. 2A). In
contrast, TGF-ÃŸ(2 ng/ml) treatment of NRK cells does not
produce any effects by itself on modifying the growth response
of these cells in the presence or absence of CHP. However, in
monolayer cultures under serum-free conditions, K-NRK cells
are approximately 16-fold more sensitive to CHP-induced
growth inhibition than are the parental NRK cells (ID50, 6 and
100 Mg/ml, respectively) (Fig. 2B). Treatment of NRK cells in
serum-free medium with TGF-Â«(2 ng/ml) or with TGF-/ÃŒ(2
ng/ml) slightly increases the sensitivity of NRK cells to CHP
(IDso, 50 and 54 Mg/ml, respectively) compared with untreated
cells within the same experiment. The combined treatment with
TGF-a and -ÃŸhas an additive effect to give the same level of
sensitivity to CHP (ID50, 8 Â¿ig/ml)as that observed in K-NRK
cells (Fig. IB).
NRK cells are not able to grow in soft agar in the absence of
TGF-a and TGF-/3 (17). In the presence of serum, NRK cells
treated with TGF-a (2 ng/ml) alone grow as colonies in soft
agar with the same efficiency as an equivalent number of K-
NRK cells (Fig. 2Q. Addition of exogenous TGF-/3 (2 ng/ml)
to TGF-a-treated NRK cells does not further increase the
number of colonies, since there may be a sufficient amount of
TGF-ÃŸalready present in the serum preparations used in this
study to cooperate with TGF-a. K-NRK cells are extremely
sensitive to the inhibitory effects of CHP in soft agar growth
(ID50, 15 Mg/ml). NRK cells treated with TGF-a or with TGF-
a and -lÃ¬exhibit the same degree of sensitivity to CHP (ID50,
20 and 18 Mg/ml, respectively) as K-NRK cells (Fig. 1C).
To determine whether the relative differences in sensitivity
to CHP could be due to variations in the rate of growth between
these different populations of cells, K-NRK or TGF-a-treated
NRK cells (2 ng/ml) were grown for various periods of time
with or without CHP (25 Mg/m') Â¡nmedium containing 10%
FBS (Fig. 3A). K-NRK cells have the fastest growth rate. TGF-
a-treated NRK cells exhibit a growth rate equivalent to that
observed in K-NRK cells and approximately 3-fold higher than
that of untreated NRK cells. In the presence of CHP, both K-
NRK and TGF-a-treated NRK cells grow more slowly and at
rates comparable to that observed with nontransformed NRK
cells. The growth inhibitory effects of CHP on K-NRK or TGF-
a-treated NRK cells were not evident until 48 h after treatment.
There was approximately a 50% growth inhibition at this point
and during subsequent growth periods. Under serum-free
growth conditions, (Fig. 2B), treatment of NRK cells with TGF-
a (2 ng/ml) for 3 days enhances by approximately 2-fold their
growth rate (75,000 cells/well in control versus 151,000 cells/
well in TGF-Â«-treated cells, respectively), whereas treatment
with TGF-/J (2 ng/ml) for 3 days does not have by itself any
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Fig. 1. Effect of CHP on morphology of
NRK cells, TGF-n-lreated NRK cells, and K-
NRK cells. The cells were grown in DMEM
containing 10% FBS for 3 days in the absence
(A, C, and E) or presence (B, D, and F) of
CHP (50 ne/mi). A, B, NRK cells; C, D, TGF-
n-treated NRK cells (2 ng/ml); E. F, K-NRK
cells.
effect on the growth rate of these cells (82,000 cells/well).
Furthermore, the combined treatment of TGF-a and -ÃŸfor 3
days has a synergistic effect on the growth rate of NRK cells,
enhancing it by approximately 10-fold to a level which is
comparable to that observed in K-NRK (795,000 cells/well in
TGF-a- and -0-treated cells and 775,000 cells/well in K-NRK
cells, respectively). However, in the presence of 10% FBS (Fig.
2A), TGF-/3 was ineffective in modifying the growth response
of NRK cells to TGF-a.
To determine whether the CHP-induced growth inhibition is
cytostatic or cytotoxic, K-NRK cells were grown in the absence
or presence of CHP (50 ng/ml) for various periods of time (Fig.
3B). CHP was then removed from half of the treated cultures
after 3 days. Under these conditions, the CHP-treated cells
resume a growth rate equivalent to that of untreated K-NRK
cells after 24 h of CHP removal. This indicates that the growth
inhibition induced by CHP is reversible and CHP is not cyto
toxic but rather cytostatic in our experiments. In addition,
trypan blue dye exclusion indicated that CHP was not cytotoxic
for either TGF-treated NRK cells or K-NRK cells (data not
shown).
Effects of TGF-a and/or -ft on Amino Acid Uptake in NRK
Cells. CHP is a proline analogue and proline uptake occurs
primarily through the neutral amino acid transport A system
(7, 8). We therefore studied the characteristics of this amino
acid transport system in NRK and K-NRK cells in the presence
or absence of TGF-a (2 ng/ml) and/or TGF-0 (2 ng/ml) to
ascertain whether changes in amino acid uptake through this
system could account for the differences in growth sensitivity
to CHP of these cells. This may be a rate-limiting step in this
response, since the Na+- and energy-dependent neutral amino
acid transport A system can be modulated by various hormones
and growth factors and uptake of amino acids through the A
system can be increased after cellular transformation (11-16).
Fig. 4 demonstrates that TGF-a or -ÃŸcan rapidly increase the
specific uptake of [3H]MeAIB in NRK cells grown in serum-
free IMEM containing transferrin (10 Mg/ml) by about 5- to 6-
fold (20 to 110 pmol/min/106 cells and 130 pmol/min/106
cells, respectively). MeAIB is a nonmetabolizable analogue of
alanine that has been routinely used to measure the activity of
the A system at pH 7.4 in the presence of Na+ (135 mivi) (15).
Enhanced uptake of [-'HJMeAIB is very rapid, reaching a max
imum within l h after TGF-a treatment and within 3 to 4 h
after TGF-0 treatment (Fig. 4). [3H]MeAIB remains elevated
for at least 16 h after treatment with TGF-a or -ÃŸ.
To determine whether the activity of the A system is com
parable in both NRK and K-NRK cells and whether this activity
can be modulated by TGFs, the uptake of ['HJMeAIB was
measured in NRK and K-NRK cells that had been treated with
TGF-a (2 ng/ml) and/or TGF-/3 (2 ng/ml) for 4 h. Compared
with untreated NRK cells, K-NRK cells exhibited an approxi
mately 7-fold increase in the uptake of [3H]MeAIB (20 and 135
pmol/min/106 cells). Treatment of K-NRK cells with TGF-a
and/or TGF-/3 did not affect the uptake of [3H]MeAIB. How-
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CHP ( CHP Ijjg mil
2. Dose-dependent inhibitory effect of CHP on growth of NRK cells, NRK cells treated with TGF-a and/or -0, and K-NRK cells. A. monolayer growth in 10%
FBS-containing medium. 2 x 10* Cells/well were seeded in 12 multiwell cluster dishes. Twenty-four h later, they were treated with different concentrations of CHP
and counted after 3 days of exposure. The cell numbers after 3 days of growth for the untreated controls were NRK cells. 144,000 cells/well; NRK cells + TGF-a (2
ng/ml), 421,000 cells/well; NRK cells + TGF-/3 (2 ng/ml), 156,000 cells/well; NRK cells + TGF-a (2 ng/ml) + TGF-0 (2 ng/ml). 442.000 cells/well; and K-NRK
cells, 441,000 cells/well. B, monolayer growth in serum-free medium. 2 x IO4Cells/well were seeded. Twenty-four h later, they were switched to serum-free medium
and treated with different concentrations of CHP and counted after 3 days of exposure. The cell numbers for the untreated controls were NRK cells, 75.000 cells/
well; NRK cells + TGF-a (2 ng/ml), 151,000 cells/well; NRK cells + TGF-/3 (2 ng/ml), 82,000 cells/well; NRK cells + TGF-a (2 ng/ml) + TGF-0 (2 ng/ml), 795.000
cells/well; and K-NRK cells, 775,000 cells/well. C, growth in soft agar. 2x10* Cells/well were seeded in 0.3% agar containing DMEM and 10% FBS in 35-mm
dishes and treated with different concentrations of CHP. The cells were grown for 12 days, stained with nitro blue tetrazolium, and counted with an Artek colony
counter. Colonies greater than 50 jim for the untreated controls were NRK cells -I-TGF-a (2 ng/ml), 1115 colonies/dish; NRK cells + TGF-a (2 ng/ml) + TGF-0 (2
ng/ml), 1135 colonies/dish; and K-NRK cells, 1200 colonies/dish. Data are expressed as percentage of cell growth compared with untreated controls. Values, average
of 3 different experiments in duplicate. The variation between the individual experiments was less than 10%. â€¢,NRK cells; A, TGF-Â«-treated NRK cells (2 ng/ml);
â€¢.TGF-0-treated NRK cells (2 ng/ml); O, NRK cells treated with TGF-a (2 ng/ml) and TGF-/3 (2 ng/ml); O, K-NRK cells.
Ã¨ 2
1 3
B.
Days of Treatment Days of Treatment
Fig. 3. A, effect of CHP on growth curves of NRK cells, TGF-a-treated NRK
cells, and K-NRK cells. Cells (2 x IO4 per well) were seeded in 12 multiwell
cluster dishes in DMEM containing 10% FBS. Twenty-four h later. NRK cells
in the presence or absence of TGF-a (2 ng/ml) and K-NRK cells were treated
with or without CHP (25 Mg/ml) and counted every day with a Coulter counter.
Results, average of 3 different experiments in duplicate. The variation between
the individual experiments was less than 10%. A, K-NRK cells; O, CHP-treated
K-NRK cells (25 ng/ml); â€¢NRK cells; â€¢,CHP-treated NRK cells (25 ng/ml);
D, TGF-a-treated NRK cells (2 ng/ml); O, NRK cells treated with TGF-a (2 ng/
ml) and CHP (25 Mg/ml). B, reversal of CHP-induced growth inhibition on K-
NRK cells. Cells (10*) were seeded in 12 multiwell cluster dishes in DMEM
containing 10% FBS. Twenty-four h later, they were treated with or without CHP
(50 nii/ml )and counted every day with a Coulter counter. After 3 days of exposure,
CHP was removed from one set of dishes. Results, average of 3 different
experiments in duplicate. The variation between the individual experiments was
less than 10%. A, K-NRK cells; Â»,CHP-treated K-NRK cells (50 Mg/ml); D, K
NRK cells rescued from CHP treatment (50 Mg/m') after 3 days.
12 14 16
Hours of Treatment
Fig. 4. Kinetics of stimulation of TGF-a or -0 on |JH]MeAIB uptake in NRK
cells. Cells (4 x IO4) were seeded in 6 multiwell cluster dishes in DMEM
containing 10% FBS. Twenty-four h later, they were washed and cultured in
serum-free 1MEM containing human transferrin (10 Mg/ml) for 16 h. The cells
were then treated for the indicated period of time with TGF-a (2 ng/ml) or TGF-
ÃŸ(2 ng/ml), and the ['HJMeAIB uptake was measured as described in "Materials
and Methods." Values, average (Â±SD)of triplicate determinations. â€¢,NRK cells;
O, TGF-a-treated NRK cells (2 ng/ml); A, TGF-0-treated NRK cells (2 ng/ml).
ever, treatment of NRK cells with TGF-a or -ÃŸincreases the
uptake of [3H]MeAIB to a level comparable to that observed in
K-NRK cells. Furthermore, addition of both TGFs produces
an additive effect on the uptake of [3H]MeAIB in NRK cells
(205 pmol/min/106 cells).
Proline is one of the several neutral amino acids that is taken
up on the A system (7, 8). To determine whether the uptake of
CHP is occurring primarily through the A system, the ability
of CHP, fra/w-hydroxyproline, and proline to inhibit the spe
cific uptake of [3H]MeAIB was measured in NRK cells, NRK
cells treated with TGF-a (2 ng/ml) or TGF-0 (2 ng/ml), and
K-NRK cells. All three amino acids are effective in inhibiting
the specific uptake of [3H]MeAIB (data not shown).
The neutral amino acid transport A system is a Na*- and
energy-dependent system (7). It has been suggested that these
requirements are controlled in part by the Na*/H* antiporter
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and Na+/K+ ATPase (25). Amiloride is a specific inhibitor of
NaYH"1"exchanger, while ouabain is a specific inhibitor of Na+/
K+ ATPase (26, 27). Each of these two drugs was therefore
tested for its ability to modify the uptake of [3H]MeAIB in
NRK cells, NRK cells treated with TGF-a (2 ng/ml) or TGF-/3
(2 ng/ml), and K-NRK cells. Cells were treated with or without
amiloride (1 HIM)or ouabain (1 HIM)for 4 h (Fig. 5). Untreated
NRK cells exhibited an intrinsic low uptake of [3H]MeAIB that
was not substantially modified by amiloride and/or ouabain
treatment. However, in NRK cells treated with TGF-a or -ÃŸor
in K-NRK cells, amiloride or ouabain each produces a 45-55%
inhibition of [3H]MeAIB uptake. Furthermore, addition of both
amiloride and ouabain to TGF-a- or -ÃŸ-treatedNRK cells or to
K-NRK cells completely abrogates the effects of these two
growth factors on stimulating the [3H]MeAIB uptake in NRK
cells and totally blocks the elevated basal uptake of [3H]MeAIB
observed in K-NRK cells (Fig. 5).
To determine whether there are any alterations in the regu
lation of the three other major amino acid transport systems
after transformation or TGF treatment of NRK cells, we meas
ured the uptake of [3H]alanine on the ASC system, [3H]leucine
on the L system, and [3H]lysine on the Ly+ system. As shown
in Fig. 6, no differences in the uptake of [3H]alanine, [3H]-
leucine, or [3H]lysine could be observed between K-NRK cells
and NRK cells treated with either TGF-a (2 ng/ml) and/or
TGF-0 (2 ng/ml) for 4 h.
DISCUSSION
The present study demonstrates that the proline analogue
CHP is a potent inhibitor of the growth of transformed rodent
fibroblast and epithelial cells. Treatment with low doses of
CHP inhibits in a dose-dependent fashion the anchorage-de
pendent and -independent growth of these transformed cells,
whereas CHP is less effective in inhibiting the growth of non-
transformed rodent fibroblast and epithelial cells. CHP is more
effective in arresting the anchorage-independent growth than
the anchorage-dependent growth of these cells. The mecha-
150
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Fig. 5. Inhibition of [3H]MeAIB uptake with ouabain and/or amiloride treat
ment in NRK cells, NRK cells treated with TGF-a or -ft, and K-NRK cells. Cells
(4 x 10* per well) were seeded in 6 multiwell cluster dishes. Twenty-four h later,
they were washed and cultured in serum-free IMEM containing human transferrin
(10 /ig/ml) for 16 h. NRK cells, TGF-a-treated NRK cells (2 ng/ml), TGF-ff-
treated NRK cells (2 ng/ml), and K-NRK cells were then incubated for 4 h in the
absence (D) or presence of ouabain (l IHM)(Ãœ)or amiloride (1 imi) d'i) or of
both ouabain and amiloride (D). The [3H]MeAIB uptake was measured as de
scribed in "Materials and Methods." Values, average (Â±SD)of three determina
tions.
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Fig. 6. Amino acid uptakes through the ASC, L, and Ly* systems in NRK
cells, NRK cells treated with TGF-Â«and/or -ft, and K-NRK cells. A, [3Hjalanine
uptake through the ASC system; B, [3H)leucine uptake through the L system; C,
[3H]lysine uptake through the Ly* system. The cells were grown as described in
Fig. 4, and amino acid uptake was measured as reported in "Materials and
Methods." NRK cells were treated for 4 h with growth factors before measuring
the specific uptake of amino acids in the absence (D) or presence of TGF-a (2
ng/ml) (Ãœ)or TGF-fi (2 ng/ml) (Ãœ)or of both TGF-a and ÃŸ(D). Values, average
(Â±SD)of three determinations.
nism(s) by which CHP selectively blocks the growth of these
transformed cell lines may be related to its ability to selectively
inhibit collagen production and secretion at low concentrations
that were used in this study (5, 6). However, several points
suggest that this may not be the case. First, normal rodent
fibroblast cell lines generally synthesize and secrete low levels
of collagen /n vitro (28). Second, the levels of collagen produc
tion and of other extracellular matrix proteins are substantially
reduced in fibroblasts after transformation (28-30). Finally, the
sensitivity of Ki-raÃ--transformed 3T3 cells to the growth-inhib
iting effects induced by CHP is not affected by culturing the
cells on dishes coated with type I or IV collagen, suggesting
that the cells cannot be rescued from the cytostatic effects of
CHP by providing them with an appropriate exogenous colla
gen matrix (see Ref. 3).3 It therefore seems unlikely that the
growth inhibitory effect induced by CHP is primarily due to
changes in levels of collagen production. It is conceivable that
CHP is inhibiting the synthesis of other structural or regulatory
proteins that contain proline or hydroxyproline. Nevertheless,
we are presently conducting experiments to address these issues,
since TGF-a and -ÃŸhave been reported to stimulate collagen
production in NRK cells (31, 32), which may partially contrib
ute to their ability to enhance the sensitivity of these cells to
the cytostatic effects of CHP.
TGF-a and -ÃŸhave been circumstantially implicated in the
autocrine growth of several types of virally, chemically, and
spontaneously transformed fibroblasts and epithelial cells (33-
38). In normal mesenchymal and in some epithelial cells, TGFs
reversibly induce several properties associated with the trans
formed phenotype, such as a loss of contact inhibition of cell
growth, a decreased requirement for serum for anchorage-
dependent growth, and the ability to grow as colonies in soft
agar. In fact, insertion of an expression vector containing the
gene for human TGF-a into normal rat 1 fibroblasts results in
the anchorage-independent growth of these cells and in the
induction of tumor formation in nude mice (39). Moreover,
anti-human TGF-Â«antibodies are able to inhibit the anchorage-
independent growth of TGF-a-expressing clones of rat 1 fibro-
3 D. S. Salomon and F. Ciardiello, unpublished results.
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blasts, suggesting that TGF-a secretion and action are through
an autocrine mechanism. Our results demonstrate that treat
ment of NRK cells with TGF-a and/or -ÃŸalso increases their
sensitivity to the growth inhibitory effects of CHP to the same
relative degree as that observed in Ki-ra.v-transformed NRK
cells. The enhanced sensitivity to the growth inhibition induced
by CHP of the transformed rodent cells may be related in part
to their ability to endogenously synthesize and secrete high
levels of biologically active TGF-a and -ÃŸ.This may be the case,
since both fibroblast and epithelial cells transformed by Ki-ros,
Ha-ras, mos, fms, and fes have been demonstrated to secrete
elevated levels of TGF-a and -ÃŸ(19, 33, 35-37).
TGF-a is a potent mitogen for the anchorage-dependent and
-independent growth of NRK cells in the presence of serum
(23, 40). In fact, TGF-a-treated NRK cells exhibit a similar
rate of growth in monolayer cultures and grow as colonies in
soft agar to the same degree as that observed in K-NRK cells.
In our studies, treatment of NRK cells in serum-containing
medium with TGF-/3 alone or in the presence of TGF-a did not
appreciably affect their anchorage-dependent or -independent
growth, presumably because there were sufficient amounts of
TGF-0 in the FBS preparations that we have used in this study
(24). Furthermore, in the presence of serum, addition of TGF-
ÃŸalone did not modify the response of NRK cells to the growth
inhibitory effects of CHP in monolayer cultures. In contrast,
TGF-a alone, in the presence of serum, was sufficient to en
hance the efficiency of CHP to inhibit the growth of NRK cells
to the same degree as that observed in K-NRK cells, both under
anchorage-dependent and -independent growth conditions. Un
der serum-free conditions, TGF-Â«was less effective in stimu
lating the growth of NRK cells than in the presence of serum.
However, in this case, the addition of TGF-/J, which by itself
did not affect the anchorage-dependent growth of NRK cells,
synergistically enhanced the growth-promoting effects of TGF-
a. In fact, under the serum-free assay conditions of these
studies, both TGF-a and -ÃŸwere required for achieving maximal
growth stimulation of NRK cells. These results are in accord
with the observations of Assoian, who has shown that TGF-/3
may function synergistically with EGF (and presumably TGF-
a) to stimulate NRK cell growth by enhancing the level of
expression of EGF receptors (41). TGF-a or -ÃŸwas able to
increase the sensitivity of NRK cells to the growth inhibitory
effects of CHP to the same degree in serum-free medium.
Addition of both growth factors to NRK cells sensitized these
cells to CHP-induced growth inhibition to the same extent as
that observed in K-NRK cells. Collectively, these results suggest
that the sensitivity of growth factor-treated NRK cells or of
transformed K-NRK cells to CHP-induced growth inhibition
may be related to or may be dependent on the intrinsic growth
rate of these cells under the various assay conditions. The only
exception to this possibility is the effect of TGF-0 on enhancing
the response of NRK cells to the growth inhibitory effects of
CHP under serum-free culture conditions, since TGF-/3 alone
has no appreciable effect on cell growth but is capable of
enhancing the uptake of [3H]MeAIB and presumably CHP.
Among the biochemical features that are frequently observed
in fibroblasts treated with growth factors or in transformed
cells are an enhanced rate of aerobic glycolysis and an increased
uptake of ions, glucose, and amino acids (11, 12, 14, 15, 42).
One major amino acid uptake system that is highly susceptible
to modulation by growth factors and constitutively elevated in
transformed cells is the neutral amino acid transport A system(11-16). The A system is a Na+- and energy-dependent uptake
system for proline, methionine, alanine, serine, and glycine (7,
8). Since CHP is a proline analogue, [3H]MeAIB uptake was
analyzed to ascertain whether this may be one of the limiting
steps that might account for the differential sensitivity to the
growth inhibition induced by CHP between normal and trans
formed cells or normal cells treated with TGF-a and/or -ÃŸ
under serum-free conditions. The present study demonstrates
that the [3H]MeAIB uptake is 6- to 7-fold higher in K-NRK
cells than in normal NRK cells. However, treatment of NRK
cells with TGF-a or -ÃŸproduced a rapid and protracted increase
in [3H]MeAIB uptake. The response to either growth factor
could be observed within 30 min of treatment and within 1 to
3 h reached a level that was 5- to 6-fold higher than in untreated
NRK cells and that was comparable to the basal level of ['HJ
MeAIB uptake observed in K-NRK cells. In contrast, K-NRK
cells were refractory to the stimulation of ['HJMeAIB uptake
induced by TGF-a and/or -ÃŸ.This may be due to the constitu
tively enhanced [3H]MeAIB uptake observed in K-NRK cells
that may be regulated in part by the endogenous production of
TGFs in these cells (33, 35). These data are in reasonable
agreement with a previous report of Boerner et al. demonstra
ting a 2- to 3-fold enhancement in MeAIB uptake in confluent
cultures of NRK cells after treatment with EGF or TGF-/3 in
the presence of serum (11). Our results further extend these
observations, since in the present study sparse cultures of NRK
and K-NRK cells were treated with TGF-a and/or -ÃŸunder
serum-free conditions to avoid any interference by other serum-
derived growth factors or hormones that could potentially mod
ulate the activity of the A system (7). In addition, we were
unable to discern a stimulatory effect of TGF-/J on the specific
uptake of MeAIB in subconfluent NRK cells grown in the
presence of serum (data not shown) or on the CHP-induced
growth inhibition of NRK cells under these culture conditions.
This may relate to the ability of TGF-fi to stimulate NRK cell
growth depending upon whether the cultures are subconfluent
or confluent (31, 41).
CHP effectively competed with |'H]MeAIB for uptake
through the A system. This demonstrates that the bulk of CHP
is probably being taken up by the neutral amino acid transport
A system in these cells. Analysis of [3H]alanine uptake on the
ASC system, pHjleucine uptake on the L system, and ['Hjlysine
uptake on the Ly+ system shows that there is no appreciable
difference in the total activity of these other three major amino
acid uptake systems between normal NRK cells and trans
formed K-NRK cells. In addition, treatment of NRK cells with
TGF-a and/or -ÃŸdid not significantly enhance the specific
uptake of ['HJalanine, ['Hjleucine, and [3H]lysine, suggesting
that the ASC, L, and Ly* systems are constitutively enhanced
in normal and transformed fibroblasts and are relatively insen
sitive to treatment with growth factors such as TGF-a and/or
-ÃŸ(15). These results agree with those of Boerner et al., who
have shown that EGF or TGF-0 fails to significantly stimulate
amino acid uptake through these other three amino acid uptake
systems in confluent cultures of NRK cells (11). Furthermore,
MeAIB uptake was found to be elevated in rat 1 fibroblasts
transformed with an activated c-Ha-ras oncogene when com
pared with nontransformed rat 1 cells and was refractory to
stimulation by TGF-0 (42).
There is a substantial amount of evidence suggesting that
growth factors, after interaction with their respective receptors,
can rapidly activate the exchange of Na+ for H+ via the Na*/
H* antiporter, which results in a transient alkalinization of the
cell (43-46). This response may be important for subsequent
DNA synthesis induced by growth factors (45, 46). The pres
ence of a viral or activated ras oncogene product may control
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either directly or indirectly the activity of Na+/H+ antiporter
(47). Furthermore, the Na*/H+ antiporter (47) is constitutively
activated in PI9 embryonal carcinoma cells and is insensitive
to modulation by growth factors, such as EGF (48). However,
differentiation of these cells into nontransformed endoderma!
cells results in the acquisition of an EGF-stimulated Na+/H+
antiporter activity. The enhanced activity of the Na+/H+ anti-
porter system after growth factor treatment or after transfor
mation may lead to an increased activity of the Na*/K+ ATPase
(25, 42). Our results demonstrate that addition of either ami-
loride or ouabain can inhibit the constitutive uptake of [3H]
MeAIB observed in K-NRK cells. Likewise, both of these
inhibitors can attenuate the TGF-a- or -/3-induced uptake of
[3H]MeAIB in serum-free grown NRK cells. Addition of both
amiloride and ouabain to K-NRK cells or to TGF-a- or -ÃŸ-
treated NRK cells reduces the uptake of [3H]MeAIB to a level
comparable to that observed in nontransformed unstimulatedNRK cells. These data circumstantially suggest that the Na~Y
H+ exchanger and the Na*/K* ATPase are in some manner
involved in the control of the activity of the amino acid trans
port A system in NRK cells after transformation or treatment
with growth factors such as TGF-a or -ÃŸ.
In summary, this study demonstrates that a number of trans
formed rodent cells or growth factor-treated normal cells are
more sensitive to the growth inhibition induced by CHP. This
differential sensitivity may be due in part to a more elevated
uptake of CHP through the neutral amino acid transport A
system after transformation or treatment of normal cells with
TGF-a and/or -ÃŸ.In addition, the data suggest that the sensi
tivity of various tumor cells to other drugs that are taken up on
the A amino acid transport system may possibly be modulated
by locally derived growth factors.
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